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Summary
Recently, it has been descnbed that elevated plasma levels of factor
VIII are a strong nsk factor for venous thtombosis We analysed the
data of the Leiden Thrombophiha Study, a population based case-
control study on the causes of venous thrombosis, to venfy whether the
nsk due to oral contiaceptive use was higher in women with higher
factor VIII levels Furthermore we mvestigated the jomt risk of high
factor VIII levels and oral contiaceptive use
We selected 155 premenopausal women with deep-vem thrombosis
and 169 control subjects, aged 15-49, who were at the time of theii
thrombosis (or similar date in conhol) not pregnant, nor m the puerpe-
num, did not have a lecent miscarnage, and were not usmg mjectable
progestogens Of the patients, 109 (70%) women had used oial contia-
ceptives durmg the month precedmg their deep-vem thiombosis, in
contiast to 65 (38%) of the control subjects (index date), yieldmg an
odds ratio for oral contiaceptive use of 3 8 (95% CI 2 4-6 0) Of the
women who suffered a deep-vem thrombosis 56 (36%) had high factor
VIII levels (>150 lU/dl) äs compaied with 29 (17%) of the control sub-
jects, yieldmg an odds ratio foi high factor VIII of 4 0 (95% CI 2 0-8 0),
relative to factor VIII levels <100 lU/dl The jomt effect of oral contia-
ceptive use and high factor VIII resulted m an odds ratio of 103
(95% CI 3 7-28 9), comparmg women who had both with women who
had neithei We conclude that there is an mcrease in nsk due to oial
contiaceptive use m women with highei factor VIII levels and that both
factors have additive effects
Introduction
Oial contraceptive use mcreases the risk of venous thrombosis, with
estimates of the relative nsk varying trom 2 1 1 (1) Recently, we
descnbed an mteraction between mal contraceptive use and carner-ship
of factor V Leiden mutation, this combmation leads to a 30-fold m-
crease in risk ot deep-vem thiombosis (2) This mteraction is relevant,
smce both factor V Leiden and oral contiaceptive use are common
Anothei common risk tactor for venous thiombosis is elevated levels
of procoagulant factor VIII (3-5) Foi men and women in the Leiden
Thrombophiha Study, high factoi VIII levels (>150 lU/dl vs <100 IU/
dl) had an odds ratio of 6 2 (95% CI 3 4-11) (3) This effect is not ex-
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plamed by elevated factor VIII levels äs a post thrombotic acute phase
reaction (4) It is plausible that high levels of factor VIII have a mixed
genetic and environmental ongm
We mvestigated whether the risk due to oral contraceptive use was
affected by factor VIII levels
Patients and Methods
The patients and methods ot our study have been descnbed previously
(2, 5) We mvited 474 consecutive patients (both sexcs) with a first episode of
proven deep vem thiombosis (diagnosed by established objective methods)
occuinng between Jan l 1988 and Dec 31, 1992 aged less than 70 years and
without a known malignanl disorder Patients had been seletted from the files
of thiee Anlicoagulation Chnics m the Netheilands, which momtor anlicoagu-
lant treatment in all patients within a well defmed geographical aiea For each
thrombosis patient we mvited one age and sex matehed healthy control sub-
ject Foi patients we uscd the date of thcir deep-vem thrombosis, for the control
subjects we used the date of their correspondmg case m the ongmal study
(index date) Patients weie seen only after anticoagulant tieatment was discon
tmued foi at least three months
Foi the picsent analysis we selected only premenopausal women, aged
15-49, who weie at the time ot then thiombosis (01 similai date m conlrol) not
piegnant, noi in the puerpei mm, did not have a recent miscarnage, and were not
usmg mjectable piogestogens
Blood collection Blood was collected mto Sarstedt Monovctte0 tubes,
contammg 0 106 mmol/l tnsodmm citrate, and mto a Becton Dickmson
Vacutamei® tubc foi blood gioup determmations Plasma was prepaied by cen
tniugation tor 10 mm at 2000 g at room temperatuie and stored at 70° C
Laboiatoi) meawiement Factor VIII coagulant aclivity (FVI11 C) was
incasuicd by one stage clottmg assays usmg factoi VIII dcficicnt plasma and
automated APTT (Organen Tekmca, Durham, US A) on a Electi a l OOOc (MLA,
Pleasantville, USA) Poolcd normal plasma, standaid cahbialed agamst the
WHO standaid toi faclor VIII was used äs a reference The technicians did
not know if the sample was Irom a patient 01 a contiol 01 hörn an oial contra
cepüve user 01 non uscr
Anal) w and staffstes We analysed data tiom 155 cases and 169 controls
about cuireni use oi oral contraceplivcs at then thrombosis- or index dale
Wc staited with umvanate analysis by unconditional legression to estimate
the odds ratio foi respectwcly oral contiaceptive use and high factor VIII
(m di l lc icnt strata) or combinations Multivanate analysis by unconditional
logistic legiession was used to ad|ust foi possible contounders, e g age, tamily
histoiy öl venous thiombosis, histoiy of pregnancy Oral contiaceptive use was
enteied dicholomously (0 for non oial contiaceptive user (cunently) and l
fo i cunent oial contraceptive use) Clottmg factor VIII was entered dicholo-
mously, l toi tactoi VIII >150 lU/dl and 0 for tactoi VIII <150 lU/dl and also
äscatcgonzedvaiiables(strata tactoi VIIK100IU/dl, 100 !25IU/dl , 125 150
I U / d l a n d > l 5 0 I U / d l )
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Although the original dala wcre age malchcd wc pciioimcd unmatched
analysis Due to ihc inclusion cntcna and age cut oll many pairs wcie no
longci mtait in the databasc Ιοί ihis analysis Smce the analysis was restncted
to the malLhmg factoi scx wc adjusted (01 confoundmg by the othei mttching
lactoi age by conlrollmg for age by logistic icgicssion Age was cnteicd mto
the models äs a contmuous variable (m yeai s) alter assessmg that usmg a cate
gonzed dummy variable modcl Icd only to tuvial difleiences lor the cstnnatois
of inteiest
tdctor VIII levels <150 lU/dl, secondly we stratified in four difieient
categones
High Factoi VIII
Dichotomous analysis showed that of the 155 women who suffered
a deep-vem thrombosis, 56 (16%) hdd high tactoi VIII levels (above
150 IlJ/dl) äs compared with 29 (17%) of the 169 control subjects,
yieldmg an odds ratio of 2 7 (95% CI l 6 4 6) Table l gives the lesults
for the categonzed levels of fdctor VIII It shows an mcreasing nsk of
venous thiombosis for incredsmg levels of factoi VIII The lesults toi
VIII are rnost ptomment if factor VIII levels are 5:150 ILJ/dl For levels
exceedmg 150 lU/dl, the nsk was 4-fold mcieased (95% CI 2 0 8 0) äs
compaied with women with factoi VIII levels <100 lU/dl
Oral Contraccptivc Use
Of the patients 109 women (70%) had used oral contraceptives
dunng the month precedmg their deep vein thrombosis m contrast to
65 (38%) of the control subjects yieldmg an odds latio toi oial contra-
ceptive use of 3 8 (95% CI 2 4 6 0)
Results
We selected from the original study 155 premenopausal women who
had hdd a deep vein thrombosis and 169 control subjects
We used two types of analysis when analysmg the faclor VIII data,
firstly we analysed simple dichotomy (factor VIII levels >150 ILJ/dl vs
Table 2 Distubution ot women with deep vcm thrombosis and contiol
subjects by oral contraceptive use (OC) and prescnce öl high lactor VIII (factor
VIII > 150 lU/dl vs factor VIII < 150 lU/dl
O C ( )
OC(+)
















Odds ntio 95 % CI
1
4 9 ( 2 8 8 6 )
45 ( 2 1 1 0 2 )
88 (4 1 18 8)
155
Table 3 Distribution öl women with dccp vein thrombosis and control
subjects by oral contraceptive use (OC) and prescnce of high factor VIII (factor
VIII >150 lU/dl vs lactor VIII <100 lU/dl)
Paticnts Controls Odd·, ratio 95% CI
OC ( )
OC (+)
O C ( )
OC( + )
FVI1I ( ) 7
F V I I I () 13
FVIII (+) 20






4 0 (l 3 12 4)
53 (l 8 155)
10 3 (37 28 9)
155 169
Oial Contiaceptive Use and Factoi VIII
Table 2 shows separate effects and combmed effects of facloi VIII
(factor VIII levels >150 lU/dl vs <150 lU/dl) and oral contiaceptive
use As the table shows the separate effects of oial contraceptive use
and high factor VIII levels aie about the same 4 9 respectively 4 5
fold mcreased nsk compared with those with normal factor VIII levels
who did not use oral contraceptives The nsk of the combmation of oral
contraceptive use and high factor VIII, compared with women with low
fdctor VIII who did not use oral contraceptives was 8 8 fold mcieased
This subdivision for oral contraceptive use was also performed for
the different stiata of factor VIII (100-125 lU/dl, 125-150 lU/dl and
>150 lU/dl) m companson with low levels of factor VIII (<100 lU/dl)
The results of the combmed effects of oral contiaceptive use and fdctor
VIII (two extreme strata of factor VIII, s 150 lU/dl compaied with
<100 lU/dl) are shown m Table 3, showmg a slightly more pronounced
effect of high factor VIII levels
The Logistic Model
The age-adjusted odds ratio for oral contraceptive use was 5 5 (95%
CI 3 2-9 6) The age adjusted odds ratio for factor VIII differed only
slightly from the crude odds ratio, with an odds ratio for those with high
factor VIII levels (S 150 lU/dl) and oral contraceptive use of 13 8 com-
pared with those with low levels of VIII (<100 lU/dl) and not usmg oial
contraceptives (Table 3) Adjustment for family history of venous
thrombosis or history of pregnancy did not change the estimators of
mterest
Incidcnce of Population
The combmed effects of factor VIII levels and oral contraceptive use
can be seen best by back-calculation to the population mcidence rates,
äs shown in Table 4 To show the absolute effect of the cumulation of
nsk factors, we estimated the population mcidence of thrombosis m
young women with the four possible combmations of high tactoi VIII
levels and use of oral contiaceptives We estimated the total number of
person yeais that had yielded the cases and partitioned these person-
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Table 4 Cuirent usc öl oial conüaceptives (OC) among patients and contiol
subjecls accordmg to piesence ot high factor VIII (>150 lU/dl)
Patients
Low factor Vlfl
No OC use 26
Current OC use 73
High factor ΥΠ!
No OC use 20





Current OC use 36 5 9
years accordmg to the distribution of oral contraceptive use and high
factor VIII levels in the control group Smce we know that m the origi-
nal study 117 female patients aged 15-49 came from the Leiden anti-
coagulation climc, which has a geographical source population of
109824 women m that age gioup (data provided by the mumcipal ad-
ministration), firstly the thrombosis mcidence among young women
without underlymg disease m the Netherlands can be estimated over the
5 years of our study äs 2 l m 10000 women-years (l 17/[5 X 109824])
Division of the number of women with venous thrombosis by the pro-
poitional number of pei son years in the categones m oral contraceptive
use and high factor VIII levels (propoitions taken from the control
group) gives estimates of the population mcidences As we know that
the population mcidence m this age bracket is about 2 1/10 000 py (2),
the 155 cases were generated by 740 000 women years of follow-up
These can be paititioned accordmg to the distribution of the control
group which represents this source population (89/51/15/14) Yielding
389704 women-years for the combination of high factor VIII (> 150IU/
dl) and oral contraceptive use The mcidence of thrombosis mcreases
from 0 7 pei 10000 women pei year foi non-useis of oral conüacep-
twes without high factor VIII to 5 9 per 10000 for those with high factor
VIII who also use oral contraceptives The absolute mcrease m throm-
bosis nsk due to oral contraceptive use (i e , nsk difference) is laiger
m women with high factor VIII than m women with low factoi VIII
(<150 lU/dl) The jomt effect of the two nsk factors is additive, m
women with low factor VIII there are 2 6 additional cases per 10000
women per year when women use oral conüaceptives and m women
with high factor VIII (non-users) theie are an additional 2 3 cases pei
10000 women per year The combination of the two nsk factois give an
additional of 5 2 cases per 10000 person-years
Discussion
We previously reported that the effect of blood group and von Wille
brand tactor, were both mediated through factor VIII in their effect on
venous thrombosis (3,6) In the present study we have mvestigated the
jomt effect of factoi VIII and oral contiaceptive use and found that their
effects are additive
In umvanate analysis, high factor VIII and oial contraceptive use
weie associated with deep-vem thrombosis (Table 1,2 and 3) The odds
ratio for oral contraceptive use among low tactor VIII was 4 0 The
odds ratio for factoi VIII among non-users was 5 3 From these odds
ratios we can calculate what to expect under different models of mter-
action Under an additive mteraction model the total excess nsk of oial
contraceptive use and factor VIII would be 8 3 (4 0 plus 5 3 minus 1)
Undei a multiplicative model, total nsk of jomt presence of factor VIII
and oial contraceptive use would be 4 0 X 5 3 = 212 The observed
data aie veiy close to the additive expectation, äs we found an odds
ratio of 10 3 Apparently, both oral contraceptive use and high factor
VIII mcrease the nsk of venous thrombosis, while thejomt presence of
both nsk factors does not lead to an excess of cases This can also be
seen in the population mcidences for the vanous nsk factors combma-
tions (Table 4)
This is diffeient from the previously reported mteraction between
factor V Leiden mutation and oral contraceptive use, which mteract m
a way that exceeded the additive expectation (2)
When adjusüng for factor V Leiden m the multivanate model with
oral contraceptive use, high factor VIII, age, family history of venous
thrombosis and panty (data not shown) the estimators of mterest did not
change This means that the nsk of high factor VIII m combination with
oral contraceptive use was not affected by factor V genotype It can be
expected that the more nsk factors (genetic or environmental) are pie-
sent, the higher the nsk of developmg venous thrombosis will be (7, 8)
Blood group and von Willebrand factor, are both mediated through
factor VIII in their effect on venous thrombosis (3) As we have shown
pieviously, m umvanate analysis bloodgroup (non-0), von Willebrand
factor levels, and factor VIII levels were all associated with nsk of
venous thrombosis In multivanate analysis, only an effect of factor
VIII levels remamed (3) Our hndmgs are m accordance with data
reported m the 1960's, descnbmg that the nsk was higher in persons
with blood group A äs compared with peisons with blood group 0, or
more generally "non-0" veisus 0 (9-12), especially dunng the use of
oral contraceptives or dunng pregnancy or pueipenum (9, 13-16) In
trymg to undei stand the biochemical mechamsm behmd these clmical
fmdmgs, lower levels of pro-coagulant factor VIII were found m nor
mal mdividuals with blood group 0 äs compared with persons with
blood group non-0 (17, 18) Subsequent research has shown that indi
viduals with non-0 blood group have higher levels of von Willebrand
factor Von Willebiand factor seives äs the carner proton of factor VIII,
and so there is a strong correlation between von Willebrand factoi
levels and factor VIII levels This led to our conclusion that factor VIII
levels were the final effector of nsk It is unclear, however, by which
mechamsm this occurs, although m analogy to other clottmg abnorma
lities with a gam of function, e g factor V Leiden, mcreased thrombin
activation seems likely The ongm of high factor VIII levels is not
entirely elucidated There exists additional famihal clustery beyond the
effects of blood gioup and von Willebiand factoi, suggestmg additional
genetic determmants (6) In addition, acquired deteimmants are likely
to play a role, too (3, 4), whether oral contraceptives mcrease factor
VIII levels is contioversial (19-24)
In the piesent study we actually did an analyses of high factor VIII
levels, bloodgroup, oial contraceptive use and venous thrombosis, but
especially among useis the data were to scarce to draw conclusions
(data not shown) Neveitheless, we found the expected relationship
between high tactor VIII and bloodgroup non-0 in explammg venous
thrombosis dunng oial contraceptive use, i e the known effect of blood
gioup on venous thrombosis, could m our data almost entirely be
explamed by high factoi VIII among non users This is m hne with the
old observation that there is a deficit of patients with blood group 0 m
subgroups of young women who develop venous thromboembohsm
durmg the use of oral conüaceptives (9)
We can conclude that there is an mcrease in nsk due to oral contra-
ceptive use m women with higher factor VIII levels and that both
factois have additive effects
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